Privia Health Group, Inc. (PRVA) Stock Price & How to Invest

Last updated November 2026

Short answer

PRVA is Privia Health Group, Inc., a Nasdaq Global Select physician-enablement company that neither employs the doctors nor owns the clinics: it organizes ~5,893 independent providers across ~25 states and Washington, DC into Privia Medical Groups, then runs their technology, billing, contracting and value-based-care programs in exchange for a slice of what those practices collect. The one thing to fix before reading any valuation of it is which line you are looking at, because roughly ~$3.69 billion of trailing Practice Collections flows across the platform, only ~$2.36 billion is recognized as GAAP revenue, ~$503 million survives as Care Margin, and ~$144 million reaches adjusted EBITDA. As of November 20, 2026 the shares closed at ~$25.30, up ~7.8% year to date and ~12.2% over one year, after a Q3 2026 report on November 5 in which revenue of ~$657 million beat consensus and full-year guidance went up again.

PRVA stock price

As of 2026-11-20, Privia Health Group, Inc. (PRVA) last closed at $25.05, up 5.5% over the past year. Over the past 52 weeks it has traded between $19.10 and $28.10.

PRVA last close
$25.05
1 day
+1.46%
1 month
+11.48%
1 year
+5.52%
52-week range
$19.10 to $28.10
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Privia Health Group, Inc.'s investor relations page. Walnut is informational, not investment advice.

PRVA key stats

At $25.05 on November 20, 2026, Privia Health Group, Inc. (PRVA) has a market cap of $3.2B and a P/E of 96.3 on trailing earnings (23.0 on forward earnings).

Market cap
$3.2B
P/E (trailing)
96.3
P/E (forward)
23.0
EPS (trailing 12 months)
$0.26
Price to book
3.9
Beta
0.75

Market cap, P/E and yield are measured at the $25.05 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Privia Health Group, Inc. (PRVA)?

The last two weeks for Privia Health Group, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • PRVA closed at $25.05 on November 20, 2026, up 2.0% over the past five trading days (from $24.55).
  • On November 18, 2026, Privia Health Group, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 19, 2026, RBC Capital raised its target to $32.00 from $31.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Privia Health Group, Inc. (PRVA) latest quarter

Privia Health reported revenue of $657 million for Q3 2026, up 13% from a year earlier (Privia Health, Nov 5, 2026).

Revenue
$657 million
up 13% from a year earlier
Diluted EPS (GAAP)
$0.10
up 100% from a year earlier
FFS-patient care
$433 million
up 23% from a year earlier

Source: Privia Health Q3 2026 results, Nov 5, 2026. Full earnings breakdown

What does Privia Health Group, Inc. (PRVA) do?

Privia Health Group is a national physician-enablement company headquartered in Arlington, Virginia, and its structure is unusual enough that it drives everything about the financials. Physicians keep owning their own Affiliated Practices and the buildings, staff and equipment inside them, and they join a single large Privia Medical Group in their market as owners of it. Privia holds the payer contracts, negotiates reimbursement, maintains the patient records and supplies the Privia Platform (technology plus revenue-cycle, population-health and administrative services) through a local management services organization, and in states where corporate ownership of medical practice is restricted the Medical Group is a Non-Owned or Friendly entity that Privia manages but does not own. As of June 30, 2026 that network covered ~5,644 implemented providers, ~1,300 practices, ~6.1 million patients and ~1,647,000 attributed lives in value-based arrangements. Revenue arrives in three shapes: fee-for-service patient care (~$803.8 million in the first half of 2026, about ~65% of the total) plus administrative fees from Non-Owned groups, value-based revenue split across capitation (~$181.3 million), shared savings (~$143.9 million) and per-member-per-month care management fees (~$38.6 million), and a small amount of other services. Of every dollar of revenue, roughly ~79% goes straight back out as provider expense to the physicians who earned it.

The investment picture is a fast compounder priced against two very different earnings numbers. For the twelve months ended June 30, 2026 Privia collected ~$3.69 billion of Practice Collections, reported ~$2.36 billion of GAAP revenue (up ~24% year over year), retained ~$503 million of Care Margin and produced ~$144 million of adjusted EBITDA against ~$28 million of GAAP net income attributable to stockholders. That ~$116 million gap is mostly non-cash stock compensation, which ran ~$41.3 million in the first half of 2026 alone and helped push shares outstanding from ~123.6 million to ~126.3 million in six months. Second-quarter 2026 results were strong on both bases: revenue ~$632.6 million (up ~21.4%), adjusted EBITDA ~$37.4 million (up ~29.1%), platform contribution margin ~52.2% versus ~49.9%, and management raised full-year 2026 guidance to the high end on Practice Collections (~$3.75 billion) and GAAP revenue (~$2.45 billion) with adjusted EBITDA now expected at the mid-to-high end of ~$145 million to ~$155 million. The third quarter, reported November 5, 2026, followed the same pattern: revenue of ~$657.0 million rose ~13.2% year over year and beat the ~$611 million consensus, adjusted EBITDA of ~$40.6 million topped the ~$39.0 million estimate, implemented providers rose by 249 in the quarter to ~5,893, and management raised 2026 guidance again, to midpoints of ~$2.53 billion of revenue and ~$155.5 million of adjusted EBITDA. Privia also agreed to buy American Choice Healthcare's Medicare Shared Savings Program ACO for ~$36 million in cash, adding ~36,000 attributed lives and three new states, and exited a Montana partnership of 69 providers. Per-share earnings on the basis Yahoo tracks were ~$0.21 against a ~$0.23 estimate, a third straight shortfall, but the shares rose after the report, and on November 18 Privia reported strong results for the 2025 Medicare Shared Savings Program performance year. At ~$25.30 per share on November 20, 2026 the market value is near ~$3.23 billion, and with ~$446.3 million of cash and essentially no debt the enterprise value is roughly ~$2.8 billion, about ~18x the guided 2026 adjusted EBITDA midpoint, ~97x trailing GAAP earnings and ~23x forward earnings. The stock is up ~7.8% year to date, ~19.3% over three months and ~12.2% over one year, recovering from a ~$18.92 52-week low after the second-quarter report and still below its ~$28.82 high. Consensus for the fourth quarter, the next report, is ~$0.27 of EPS on ~$662.9 million of revenue.

What's driving Privia Health Group, Inc. (PRVA)?

1. Provider adds and new-market entry drive the top line

Implemented providers reached ~5,644 at June 30, 2026, up ~10.1% year over year, and management kept full-year guidance at ~5,900 to ~6,000. Each added provider brings their existing patient panel and collections onto the platform without Privia buying the practice, which is why Practice Collections grew ~12.4% in the quarter to ~$970.0 million while capital expenditure stayed near zero and net property and equipment sat at ~$0.3 million. Growth comes from three routes at once: recruiting independent practices in the ~25 states already served, entering new states, and the lighter Privia Care Partners affiliation model for providers who want only the value-based-care infrastructure. By September 30, 2026 implemented providers reached ~5,893, up 249 in the quarter and already near the top of the full-year range, even after the exit of a 69-provider Montana partnership.

2. The mix is shifting toward value-based care, which carries more margin and more risk

Attributed lives rose ~19.2% to ~1,647,000, already at the top of the raised full-year range of ~1,625,000 to ~1,650,000. Value-based revenue (capitation, shared savings and care management fees) reached ~$363.8 million in the first half of 2026, about ~29% of revenue, with shared savings up ~33% and capitated revenue up ~24% year over year. That shift is why Care Margin grew ~18.3% in the half against ~23.5% revenue growth on a much smaller base, but it also means Privia now carries medical-cost risk on part of the book: unpaid claim liabilities under at-risk capitation stood at ~$99.0 million, and the first half benefited from ~$13.2 million of favorable prior-year reserve development that will not repeat automatically. In Q3 2026 Privia added to the value-based side by agreeing to acquire American Choice Healthcare's Medicare Shared Savings Program ACO for ~$36 million in cash, which brings ~36,000 attributed lives across 10 existing and 3 new states, and on November 18, 2026 it reported strong results for the 2025 MSSP performance year.

3. Operating leverage is showing up in the platform line

Cost of platform, the fixed-ish spend on technology, support and shared services, grew only ~6.8% in the second quarter against ~14.7% Care Margin growth, which lifted platform contribution margin to ~52.2% from ~49.9% and adjusted EBITDA margin (measured against Care Margin) to ~28.3% from ~25.2%. Adjusted EBITDA rose ~29.1% in the quarter and ~32.6% for the half, roughly ~1.4x the pace of Care Margin. GAAP operating income remains thin at ~$11.8 million on ~$632.6 million of revenue because stock compensation and intangible amortization sit inside those lines, so the leverage is visible in the non-GAAP progression well before it is visible in reported profit. Q3 2026 adjusted EBITDA of ~$40.6 million came in ahead of the ~$39.0 million estimate, and year to date adjusted EBITDA ran at ~28.8% of Care Margin against a stated 30% to 35% long-term target.

4. A net-cash balance sheet with no leverage in the story

Privia held ~$446.3 million of cash at September 30, 2026 against essentially no debt (~$8.3 million), up from ~$412.2 million at June 30, 2026, when total liabilities of ~$650.5 million that are almost entirely provider liability (~$541.4 million, money owed onward to practices) and accounts payable. Cash covers roughly ~14% of the market capitalization, and management guided to converting ~70% to ~80% of full-year 2026 adjusted EBITDA into free cash flow, subject to the timing of the Medicare Shared Savings Program cash settlement. That funds tuck-in market entries (~$11.4 million of acquisitions in the first half, versus ~$89.1 million in the prior-year half, plus the ~$36 million American Choice ACO deal agreed in Q3) without dilution beyond the equity compensation the company already issues.

What are the risks to Privia Health Group, Inc. (PRVA)?

Payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle. Cash flow itself is lumpy in a way the annual figure hides, because operating activities used ~$48.4 million in the first half of 2026 (versus ~$16.1 million used in the prior-year half) as accounts receivable built by ~$172.4 million ahead of shared-savings settlements, even though full-year 2025 operating cash flow was positive at ~$163.4 million. On March 24, 2026, after making a voluntary disclosure, Privia received a Request for Information or Assistance from the Department of Health and Human Services Office of Inspector General regarding a single former obstetric and gynecological Affiliated Practice in the Mid-Atlantic and whether it procured and implanted medical devices without complying with applicable requirements; the company is cooperating with OIG, the Department of Justice and the Virginia Attorney General, says it is unaware of similar conduct elsewhere, and does not currently expect a material adverse effect, but the scope is not yet determined. Structurally, most of the economics belong to the doctors (provider expense is ~79% of revenue), the physicians are independent and can leave, and the terms of Medicare Shared Savings, capitated and commercial value-based programs are set by CMS and payers rather than by Privia, so a rule change can reprice the fastest-growing revenue line. Finally, the valuation carries no cushion on reported earnings at roughly ~97x trailing GAAP net income as of November 20, 2026, and closing the gap to the ~$1.04 of trailing adjusted EPS requires accepting ~$71.1 million of annualized stock compensation as a non-expense while the share count keeps rising. Two smaller near-term watch items: EPS on the basis Yahoo tracks missed consensus in Q1, Q2 and Q3 2026 (~$0.19 versus ~$0.25, ~$0.19 versus ~$0.24 and ~$0.21 versus ~$0.23), so the raised guidance has yet to convert into per-share beats, and a Barron's roundup on September 18, 2026 listed Privia among companies with new activist filings at the SEC, without detail on who filed or what they seek.

What is the Privia Health Group, Inc. (PRVA) forecast?

17 analysts publish price targets on PRVA, averaging $31.82 as of November 2026, or +27.0% against the $25.05 share price on November 20, 2026. The published targets run from $24.00 to $39.00, a moderate spread, and the ratings split 17 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PRVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is PRVA a buy or a sell?

We give no verdict on Privia Health Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Provider adds and new-market entry drive the top line. Implemented providers reached ~5,644 at June 30, 2026, up ~10.1% year over year, and management kept full-year guidance at ~5,900 to ~6,000. The most optimistic published target, $39.00, assumes this works close to its best case.

The case against. Payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle. The most pessimistic target, $24.00, is roughly what PRVA is worth if this bites instead.

Read the full bull and bear case on PRVA, including what would have to change to break either one. Walnut is not an investment adviser.

Has Privia Health Group, Inc. (PRVA) split its stock?

No. Privia Health Group, Inc. (PRVA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Privia Health Group, Inc. (PRVA) valued?

Market cap, P/E and dividend yield at today's price are in the PRVA key stats above. The business figures below come from Privia Health Group, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$2.43 billion GAAP revenue for the twelve months to September 30, 2026; Q3 2026 revenue ~$657.0 million, up ~13.2% and ahead of the ~$611 million consensus. 2026 guidance raised again on November 5 to a ~$2.53 billion revenue midpoint
  • Practice Collections vs revenue: Practice Collections of ~$3.69 billion flowed through the platform in the twelve months to June 30, 2026, against ~$2.36 billion of GAAP revenue over the same period; the difference is collections at Non-Owned Medical Groups that Privia manages but does not consolidate
  • Adjusted EBITDA: Q3 2026 ~$40.6 million versus a ~$39.0 million estimate; 2026 guidance midpoint ~$155.5 million; year to date ~28.8% of Care Margin
  • Earnings, GAAP versus Yahoo-tracked EPS: Trailing GAAP net income ~$34.8 million (~$0.26 per share), profit margin ~1.4%; Q3 2026 net income ~$13.5 million. Q3 EPS on Yahoo's basis ~$0.21 versus a ~$0.23 estimate; stock compensation is the main gap to adjusted earnings
  • Balance sheet and cash: ~$446.3 million cash and ~$8.3 million of debt at September 30, 2026; trailing operating cash flow ~$108 million and free cash flow ~$84 million
  • Market pricing: ~$25.30 per share on November 20, 2026 for a market value near ~$3.23 billion and an enterprise value near ~$2.8 billion. That is ~97x trailing GAAP earnings, ~23x forward earnings, ~1.3x sales and ~4.0x book; 52-week range ~$18.92 to ~$28.82
  • Analysts and next report: 17 analysts, average target ~$31.82, consensus Strong Buy (RBC raised to ~$32 on November 19); Q4 2026 consensus EPS ~$0.27 on ~$662.9 million of revenue; 2027 consensus EPS ~$1.09 on ~$2.80 billion of revenue

As of November 2026: Operating figures are approximate and drawn from the Q3 2026 report, the Q2 2026 Form 10-Q and Yahoo Finance data, with market pricing as of November 20, 2026, so verify live data before acting on any of them. PRVA screens at ~1.3x sales and ~97x earnings at once because the sales figure includes the ~79% of revenue paid straight to physicians while the earnings figure is after tens of millions of annual stock compensation, so neither multiple describes the business on its own. The cleanest single comparison is enterprise value against adjusted EBITDA, roughly ~18x the guided 2026 midpoint, held next to double-digit revenue growth, ~19% attributed-lives growth and a debt-free balance sheet.

Who competes with Privia Health Group, Inc. (PRVA)?

Physician enablement and value-based care enablers

The closest public comparisons are agilon health, Astrana Health, P3 Health Partners and Evolent Health, plus private players including Aledade, Wellvana and Vytalize, all competing to sign independent primary-care practices into shared-savings and capitated arrangements. The distinction that matters is how much medical-cost risk each one takes: Privia's book is still majority fee-for-service with value-based revenue at ~29% of the total, whereas the full-risk models carry more upside per life and far more exposure to medical loss ratios. Several of the deep-risk operators repriced sharply when Medicare Advantage costs ran hot, which is the main reason investors scrutinize Privia's ~$99.0 million of unpaid at-risk claim liabilities.

Payer-owned and health-system-owned physician groups

UnitedHealth's Optum, CVS Health's Oak Street Health, Amazon's One Medical and Humana's CenterWell compete for the same independent practices, but they buy or employ rather than enable, and regional health systems do the same at local scale. Privia's pitch against them is that physicians keep ownership of their practices and a governance seat in the Medical Group instead of becoming employees, which is the structural feature its whole model rests on. That also caps what Privia can extract, because the doctors keep roughly ~79% of the revenue their work generates.

Practice technology and revenue-cycle vendors

On the tooling side the alternative to the Privia Platform is assembling it yourself from an electronic health record such as athenahealth, Epic or eClinicalWorks plus a revenue-cycle vendor such as R1 RCM or Veradigm and a separate population-health layer. Those vendors sell software; Privia bundles software with payer contracting, credentialing, staffing support and value-based program administration into one arrangement priced as a share of collections. Losing on this axis looks like practices unbundling rather than switching wholesale, which shows up slowly in implemented-provider retention rather than in a single lost contract.

What stocks are similar to Privia Health Group, Inc. (PRVA)?

Other names that sit close to PRVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Privia Health Group, Inc. (PRVA)

There are three common ways to get PRVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PRVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PRVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Privia Health Group, Inc. (PRVA)

Privia is a debt-free, asset-light aggregator of independent physicians growing collections and attributed lives at double digits, whose economics only make sense line by line, since the headline collections number is roughly ~26 times the adjusted EBITDA it actually produces. In late November 2026 the market values it near ~$3.23 billion, about ~23x forward earnings, while 17 analysts average a ~$31.82 target.

More on Privia Health Group, Inc. (PRVA)

Whether PRVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PRVA a buy or a sell?, and where the stock could go from here in the PRVA stock forecast.

For income investors, whether PRVA pays a dividend and how the payout looks is covered in does PRVA pay a dividend? And to weigh PRVA against a peer, read the full side-by-side comparisons: PRVA vs AGL and PRVA vs ASTH.

Wondering how PRVA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Privia Health Group, Inc.

Ask Walnut's AI anything about PRVA and see how it fits what you own.

FAQ

What does Privia Health actually do?

+

It organizes independent physician practices into large regional medical groups and runs the business side for them. Doctors keep owning their own Affiliated Practices, the space, staff and equipment, and they join the Privia Medical Group in their market as owners of it. Privia holds the payer contracts, negotiates reimbursement rates, maintains patient records, supplies the technology and revenue-cycle platform, and enrolls those providers in value-based programs through its own accountable care organizations. As of June 30, 2026 the network spanned ~5,644 implemented providers, ~1,300 practices and ~6.1 million patients across ~25 states and Washington, DC, and implemented providers reached ~5,893 by September 30, 2026.

Why does PRVA show a PE ratio above 100 when adjusted earnings look so much larger?

+

Because GAAP net income is after non-cash stock compensation and Privia's adjusted figures are not. Trailing net income attributable to stockholders is ~$28.1 million, or ~$0.22 per share, against ~$136 million of trailing adjusted net income, or ~$1.04 per diluted share, and the bridge is mostly ~$71.1 million of annualized stock compensation plus intangible amortization and non-recurring items. Using trailing figures to September 30, 2026, GAAP EPS is ~$0.26, so at ~$25.30 on November 20, 2026 the stock is ~97x trailing GAAP earnings and ~23x forward estimates. The stock compensation is genuinely non-cash, but it is not costless: shares outstanding rose from ~123.6 million to ~126.3 million in the six months to June 30, 2026.

What is the difference between Practice Collections, revenue and Care Margin?

+

They are three different points along the same dollar. Practice Collections is everything collected across all practices in all markets from all sources, ~$3.69 billion on a trailing basis, and it includes collections at Non-Owned Medical Groups that Privia manages but does not consolidate. GAAP revenue, ~$2.36 billion, is the portion Privia recognizes on its own income statement. Care Margin, ~$503 million, is revenue minus provider expense (the money paid onward to physicians) and before intangible amortization, so it approximates what Privia keeps to run itself. Adjusted EBITDA of ~$144 million is what survives after platform, sales and administrative costs, about ~3.9% of the collections headline.

Is Privia Health profitable?

+

Yes on both bases now, though only modestly on GAAP. Full-year 2025 net income attributable to stockholders was ~$22.9 million on ~$2.12 billion of revenue, and the trailing twelve months to June 30, 2026 came to ~$28.1 million. Q2 2026 net income was ~$9.0 million, up ~236.7% year over year, with operating income of ~$11.8 million. Adjusted EBITDA is much larger at ~$37.4 million for the quarter and ~$144 million trailing. Free cash flow is guided at ~70% to ~80% of full-year 2026 adjusted EBITDA, with the caveat that the first half used ~$48.4 million of operating cash because receivables build ahead of shared-savings settlements.

What is Privia's 2026 guidance and did it change?

+

On August 6, 2026 the company raised most of it. Attributed lives went to ~1,625,000 to ~1,650,000 from ~1,550,000 to ~1,600,000, Practice Collections and GAAP revenue were pointed to the high end of ~$3.65 to ~$3.75 billion and ~$2.35 to ~$2.45 billion respectively, and Care Margin (~$515 to ~$530 million), platform contribution (~$260 to ~$270 million) and adjusted EBITDA (~$145 to ~$155 million) were pointed to the mid-to-high end. Implemented-provider guidance was unchanged at ~5,900 to ~6,000. Guidance assumes no new business development activity, meaning acquisitions and new-market deals are upside to the numbers rather than inside them. On November 5, 2026, with Q3 results, management raised the outlook again, above the high end of its initial ranges for all key metrics, to midpoints of ~$2.53 billion of revenue and ~$155.5 million of adjusted EBITDA.

Does PRVA pay a dividend?

+

No. Privia Health has never declared a dividend and there is no stated payout policy, so the total return case rests entirely on the share price. The company held ~$446.3 million of cash at September 30, 2026 with no debt and directs capital toward entering new markets, tuck-in acquisitions of management services organizations and providers, and the equity compensation it uses to pay staff. Analyst consensus in November 2026 sits near ~$31.82 against a ~$25.30 price, which is a forecast rather than a fact and has been wrong in both directions across the stock's history since its April 2021 IPO.

What is the OIG inquiry disclosed in the 10-Q?

+

On March 24, 2026, after Privia made a voluntary disclosure to federal and state authorities, it received a Request for Information or Assistance from the Department of Health and Human Services Office of Inspector General. The inquiry concerns a single obstetric and gynecological Affiliated Practice formerly in Privia's Mid-Atlantic service area and whether that practice procured and implanted medical devices for a limited group of patients without complying with applicable regulatory requirements. Privia says it is not aware of similar conduct at other Affiliated Practices, is cooperating with OIG while coordinating with the Department of Justice and the Virginia Attorney General, and does not currently believe the matter is reasonably likely to be material, while noting it can give no assurance about the eventual scope.

How is Privia different from Optum or agilon health?

+

Optum, CVS's Oak Street Health and Humana's CenterWell buy practices and employ doctors; Privia leaves ownership with the physicians and sells them a platform plus payer contracting in exchange for a share of collections, which is why provider expense runs at ~79% of revenue. agilon health, Astrana Health and P3 Health Partners are closer structurally but sit further out on the risk curve, taking full or near-full capitation on Medicare populations, whereas Privia's book is still majority fee-for-service with value-based revenue at ~29% of the first-half 2026 total. That mix means less upside per attributed life and less exposure when medical costs run above expectation, which is the trade-off at the center of comparing them.

How did Privia Health do in its latest quarter?

+

Q3 2026, reported November 5, revenue was ~$657.0 million, up ~13.2% year over year and ahead of the ~$611 million consensus; adjusted EBITDA was ~$40.6 million against a ~$39.0 million estimate, GAAP net income was ~$13.5 million, and implemented providers rose by 249 to ~5,893. Management raised 2026 guidance again and agreed to buy American Choice Healthcare's MSSP ACO for ~$36 million. EPS on the basis Yahoo tracks was ~$0.21 against ~$0.23, a third straight shortfall on that measure, yet the shares rose after the report. The prior quarter (Q2) had revenue of ~$632.6 million, up ~21.4%.

How has PRVA stock performed in 2026?

+

PRVA closed at ~$25.30 on November 20, 2026, up ~7.8% year to date and ~12.2% over one year, within a 52-week range of ~$18.92 to ~$28.82. It gained ~12.9% over the latest month, helped by the Q3 report and raised guidance, and ~19.3% over three months. Walnut is not an investment adviser, and these figures describe past movement only.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Privia Health Group, Inc.'s investor relations page or your broker before making investment decisions.